- Home
- ACXP vs APRE Comparison
ACXP vs APRE Comparison
Compare ACXP & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACXP | APRE |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8M | 6.3M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ACXP | APRE |
|---|---|---|
| Price | $1.48 | $0.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $143.67 | $5.50 |
| AVG Volume (30 Days) | 47.6K | ★ 420.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 24.35 | ★ 37.97 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $0.55 |
| 52 Week High | $8.34 | $2.79 |
Technical Indicators
Market Signals| Indicator | ACXP | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 24.66 | 56.03 |
| Support Level | $0.30 | $0.55 |
| Resistance Level | $2.89 | $1.02 |
| Average True Range (ATR) | 0.17 | 0.09 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 11.03 | 83.78 |
Price Performance
Historical ComparisonAbout ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
About APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.